LONGBIO-B(01779) has been included in the stock lists of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.
Tianchen Biotechnology-B (01779) announced that, according to the notice on the adjustment of eligible securities under the Shanghai-Hong Kong Stock Connect issued by the Shanghai Stock Exchange on September 4, 2026, and the announcement on the adjustment of the Hong Kong Stock Connect eligible securities list under the Shenzhen-Hong Kong Stock Connect issued by the Shenzhen Stock Exchange on September 7, 2026, the company has been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective from September 7, 2026. After being included in the eligible securities list, qualified investors in mainland China will be able to directly trade the company's shares through the Shanghai Stock Exchange and Shenzhen Stock Exchange.
LONGBIO-B (01779) announced that, according to the notice issued by the Shanghai Stock Exchange on September 4, 2026, regarding adjustments to the eligible securities under the Stock Connect program, and the announcement made by the Shenzhen Stock Exchange on September 7, 2026, concerning adjustments to the list of eligible securities under the Shenzhen-Hong Kong Stock Connect program, the company has been included in the list of eligible securities for both Stock Connect programs, effective from September 7, 2026. After the company's shares are included in the list of eligible securities, qualified investors in mainland China will be able to buy and sell shares directly through the Shanghai and Shenzhen Stock Exchanges.
The Board of Directors believes that the inclusion of the shares in the trading mechanisms of the Stock Connect programs demonstrates the market's high recognition of the investment value and growth prospects of the company. The company expects that being included in the list of eligible securities will further help to expand the shareholder base, attract more long-term institutional investors, increase the trading liquidity of the shares, and lay a solid foundation for the company's long-term development, thereby enhancing the company's investment value and reputation in the capital markets.
Related Articles

BIOHEART-B(02185) has appointed GIORGIO GOBBI as Vice President of Global Therapeutic Development at Antong.

Dencare (001328.SZ) indirect controlling shareholders concerted action party intends to reduce its holdings by no more than 1.74%.

POLY XVERSE IT (00209): Zhao Kai resigns as Chairman and Executive Director
BIOHEART-B(02185) has appointed GIORGIO GOBBI as Vice President of Global Therapeutic Development at Antong.

Dencare (001328.SZ) indirect controlling shareholders concerted action party intends to reduce its holdings by no more than 1.74%.

POLY XVERSE IT (00209): Zhao Kai resigns as Chairman and Executive Director

RECOMMEND





